Capital Fund Management S.A. Has $4.37 Million Stake in Amicus Therapeutics, Inc. $FOLD

Capital Fund Management S.A. increased its stake in Amicus Therapeutics by 144% in Q2, owning 762,698 shares worth $4.37 million. Amicus reported Q3 EPS of $0.17, beating estimates. Insiders sold shares, reducing ownership. Analysts upgraded ratings, with JPMorgan raising the target price to $19.00. Amicus stock opened at $9.80, with a market cap of $3.02 billion.

Capital Fund Management S.A. raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 144.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 762,698 shares of the biopharmaceutical company's stock after buying an additional 450,137 shares during the period. Capital Fund Management S.A. owned 0.25% of Amicus Therapeutics worth $4,370,000 at the end of the most recent reporting period.

Get Amicus Therapeutics alerts:

Time to buy these 3 healthcare companies that raised revenue guidance?

A number of other large investors also recently modified their holdings of FOLD. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the first quarter valued at about $30,000. PNC Financial Services Group Inc. increased its position in shares of Amicus Therapeutics by 211.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 3,497 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Amicus Therapeutics during the 1st quarter worth approximately $53,000. CWM LLC boosted its holdings in shares of Amicus Therapeutics by 395.9% in the 2nd quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 7,502 shares during the last quarter. Finally, Inceptionr LLC acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at approximately $61,000.

Amicus Therapeutics Trading Down 1.3%

Shares of FOLD stock opened at $9.80 on Tuesday. The company has a market capitalization of $3.02 billion, a PE ratio of -81.66 and a beta of 0.66. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 12-month low of $5.51 and a 12-month high of $10.57. The firm has a 50 day moving average price of $8.82 and a two-hundred day moving average price of $7.43.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The business had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. During the same period in the previous year, the company posted $0.10 EPS. The firm's quarterly revenue was up 19.5% on a year-over-year basis. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Insider Buying and Selling at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,643 shares of the company's stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $10.10, for a total value of $258,994.30. Following the transaction, the insider directly owned 296,975 shares in the company, valued at approximately $2,999,447.50. This represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Ellen Rosenberg sold 23,621 shares of the firm's stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total transaction of $236,210.00. Following the transaction, the insider directly owned 507,710 shares in the company, valued at approximately $5,077,100. This represents a 4.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 201,652 shares of company stock worth $2,019,288. Insiders own 2.20% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on FOLD. Wall Street Zen upgraded shares of Amicus Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Zacks Research upgraded shares of Amicus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. JPMorgan Chase & Co. raised their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an "overweight" rating in a research note on Thursday, November 6th. Needham & Company LLC upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 price target for the company in a report on Thursday, September 18th. Finally, The Goldman Sachs Group boosted their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $16.57.

View Our Latest Stock Analysis on Amicus Therapeutics

About Amicus Therapeutics

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Should You Invest $1,000 in Amicus Therapeutics Right Now?

Before you consider Amicus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.

While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here